Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results.
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potenti…
Ernexa Therapeutics appointed Robert J. Spiegel, M.D., FACP, to its Board of Directors as it advances ERNA-101 toward clinical development.
Ernexa Therapeutics appointed biopharmaceutical executive Robert J. Spiegel, M.D., FACP, to its Board of Directors. The company said the appointment strengthens the board as it advances ERNA-101 toward clinical development.
ERNA Ernexa Therapeutics CEO corner highlights differentiated erna-101 platform as company advances toward planned first-in-human phase 1 study in 2026
Ernexa Therapeutics moves forward with ERNA-101, targeting Q3 IND filing. This development may impact the biotech sector.